Marvel Biosciences Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRVL.V research report →
Companymarvelbiotechnology.com
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor.
- CEO
- J. Roderick Matheson
- IPO
- 2021
- Employees
- 5
- HQ
- Calgary, AB, CA
Price Chart
Valuation
- Market Cap
- $9.45M
- P/E
- -4.17
- P/S
- 0.00
- P/B
- -2.25
- EV/EBITDA
- -6.36
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 57.76%
- ROIC
- 74.74%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,211,468 · -133928.36%
- EPS
- $-0.05 · 99.89%
- Op Income
- $-1,248,683
- FCF YoY
- 2.47%
Performance & Tape
- 52W High
- $0.40
- 52W Low
- $0.07
- 50D MA
- $0.16
- 200D MA
- $0.17
- Beta
- 0.62
- Avg Volume
- 56.64K
Get TickerSpark's AI analysis on MRVL.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MRVL.V Coverage
We haven't published any research on MRVL.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MRVL.V Report →